AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has ...

Among some other larger deals, AbbVie acquired ImmunoGen last year ... see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked ...

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy. Read why I’m maintaining ...

The North Chicago drugmaker could have a new foe — or frenemy — in a fellow Big Pharma firm trying to find wider uses for its ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

We recently compiled a list of the 14 Best 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

AbbVie delivered Y/Y growth in Q2 despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers. Read why I remain bullish on ABBV stock.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $209.00. The company’s shares closed ...

We recently compiled a list of the 10 Best Cosmetic Surgery and Aesthetics Stocks To Buy. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other ...

In February, management completed the acquisition of ImmunoGen ... AbbVie currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks ...

Among some other larger deals, AbbVie acquired ImmunoGen last year, which added the latter’s ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest ...